Search the web
Welcome, Guest
[Sign Out, My Account]
EDGAR_Online

Quotes & Info
Enter Symbol(s):
e.g. YHOO, ^DJI
Symbol Lookup | Financial Search
KBIO > SEC Filings for KBIO > Form 8-K on 24-Jun-2013All Recent SEC Filings

Show all filings for KALOBIOS PHARMACEUTICALS INC | Request a Trial to NEW EDGAR Online Pro

Form 8-K for KALOBIOS PHARMACEUTICALS INC


24-Jun-2013

Entry into a Material Definitive Agreement, Unregistered Sale of Equ


Item 1.01 Entry into a Material Definitive Agreement.

On June 19, 2013, KaloBios Pharmaceuticals, Inc. (the "Company") entered into Amendment No. One (the "Amendment") to its Loan and Security Agreement, dated as of September 5, 2012, with MidCap Financial SBIC, LP ("MidCap") to (i) require the Company to draw down the third tranche of $5,000,000 and (ii) extend the date by which the Company must draw down the third tranche of $5,000,000 from June 30, 2013 to May 30, 2014. In addition, pursuant to the terms of the Amendment, the principal payments for the third tranche shall begin on the later of January 1, 2014 or the first day of the month after the Company draws down the third tranche.

The foregoing description of the material terms of the Amendment is qualified in its entirety by reference to the full text of the Amendment, a copy of which is filed herewith as Exhibit 10.1 to this Current Report on Form 8-K and is incorporated herein by reference.

In connection with the Amendment, the Company issued a warrant (the "Warrant") to MidCap to purchase up to 49,548 shares of the Company's Common Stock with an exercise price of $12.11 per share. The Warrant is immediately exercisable and expires on June 19, 2023. The Company issued the Warrant in reliance on the exemption from registration provided by Section 4(2) of the Securities Act of 1933.



Item 3.02 Unregistered Sales of Equity Securities.

The information set forth in Item 1.01 in connection with the Warrant is incorporated in this Item 3.02 by reference.



Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 19, 2013, the Company held its Annual Meeting of Stockholders (the "Annual Meeting"). At the Annual Meeting, the Company's stockholders voted on two proposals, each of which is described in more detail in the Company's definitive proxy statement on Schedule 14A and filed with the Securities and Exchange Commission on April 29, 2013. Only stockholders of record as of the close of business on April 22, 2013, the record date for the Annual Meeting, were entitled to vote at the Annual Meeting. As of the record date, 24,148,315 shares of the Company's common stock were outstanding and entitled to vote at the Annual Meeting. The tabulation of the stockholders votes on each proposal brought before the Annual Meeting is as follows:

Proposal 1: The election of eight directors to hold office until the 2014 annual meeting of stockholders and until his or her successor is elected and qualified:

                                                                  BROKER
           NAME                             FOR       WITHHELD   NON-VOTES
           David W. Pritchard            13,478,851    4,271     1,351,393
           James I. Healy, M.D., Ph.D.   12,964,406   518,716    1,351,393
           Denise Gilbert, Ph.D.         13,478,285    4,837     1,351,393
           Dennis Henner, Ph.D.          13,477,640    5,482     1,351,393
           Ted W. Love, M.D.             13,210,863   272,259    1,351,393
           Gary Lyons                    12,973,502   509,620    1,351,393
           Brigitte Smith                13,478,851    4,271     1,351,393
           Raymond M. Withy, Ph.D.       13,106,902   376,220    1,351,393


Proposal 2: The ratification of the appointment, by the audit committee of the Board of Directors, of Ernst & Young LLP as the Company's independent registered public accounting firm for the year ending December 31, 2013

FOR AGAINST ABSTENTIONS
14,832,244 1,971 300

As a routine proposal under applicable rules, no broker non-votes were recorded in connection with this proposal.



Item 9.01 Financial Statements and Exhibits.

The following Exhibits are filed as part of this Current Report on Form 8-K.

(d) Exhibits

Exhibit Number                                  Description

10.1                   Amendment No. One to Loan and Security Agreement, by and
                       between KaloBios Pharmaceuticals, Inc. and MidCap Financial
                       SBIC, LP, dated as of June 19, 2013.

10.2                   Warrant to Purchase Stock, by and between KaloBios
                       Pharmaceuticals, Inc. and MidCap Financial SBIC, LP, dated as
                       of June 19, 2013.


  Add KBIO to Portfolio     Set Alert         Email to a Friend  
Get SEC Filings for Another Symbol: Symbol Lookup
Quotes & Info for KBIO - All Recent SEC Filings
Sign Up for a Free Trial to the NEW EDGAR Online Pro
Detailed SEC, Financial, Ownership and Offering Data on over 12,000 U.S. Public Companies.
Actionable and easy-to-use with searching, alerting, downloading and more.
Request a Trial      Sign Up Now


Copyright © 2014 Yahoo! Inc. All rights reserved. Privacy Policy - Terms of Service
SEC Filing data and information provided by EDGAR Online, Inc. (1-800-416-6651). All information provided "as is" for informational purposes only, not intended for trading purposes or advice. Neither Yahoo! nor any of independent providers is liable for any informational errors, incompleteness, or delays, or for any actions taken in reliance on information contained herein. By accessing the Yahoo! site, you agree not to redistribute the information found therein.